We're continuously improving your experience and this page will be retired soon. If you rely on the content on this page, check out Screeners Beta for similar content and functionality.
The Fight Against COVID19
23.85k followers • 13 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Performance
| Watchlist | Change Today | 1 Month Return | 1 Year Return | Total Return |
|---|---|---|---|---|
| The Fight Against COVID19 | -0.99% | - | - | - |
| ^GSPC | +0.38% | +3.73% | +35.79% | +6346.82% |
13 Symbols
| Symbol | Company Name | Last Price | Change | % Change | Market Time | Volume | Avg Vol (3 month) | Market Cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 155.47 | -1.26 | -0.80% | 4:00 PM EST | 8.82M | 6.13M | 374.31B |
| ABBV | AbbVie Inc. | 199.5 | -1.01 | -0.50% | 4:00 PM EST | 4.59M | 4.70M | 352.54B |
| PFE | Pfizer Inc. | 26.72 | -0.32 | -1.18% | 4:00 PM EST | 53.55M | 32.22M | 151.42B |
| SNY | Sanofi | 51.32 | -0.41 | -0.79% | 4:00 PM EST | 1.28M | 1.74M | 128.78B |
| GILD | Gilead Sciences, Inc. | 96.565 | -1.33 | -1.36% | 4:00 PM EST | 7.46M | 6.22M | 120.32B |
| REGN | Regeneron Pharmaceuticals, Inc. | 828.42 | +3.94 | +0.48% | 4:00 PM EST | 563.54k | 642.13k | 91.04B |
| GSK | GSK plc | 36.29 | -0.37 | -1.01% | 4:00 PM EST | 8.87M | 4.92M | 74.04B |
| TAK | Takeda Pharmaceutical Company Limited | 13.78 | -0.08 | -0.58% | 4:00 PM EST | 984.23k | 1.65M | 43.69B |
| BNTX | BioNTech SE | 110.64 | +2.76 | +2.56% | 4:00 PM EST | 1.22M | 991.30k | 26.52B |
| MRNA | Moderna, Inc. | 46.83 | -3.45 | -6.86% | 4:00 PM EST | 13.48M | 5.30M | 18.02B |
| NVAX | Novavax, Inc. | 8.91 | -0.27 | -2.94% | 4:00 PM EST | 3.75M | 5.94M | 1.43B |
| VIR | Vir Biotechnology, Inc. | 9.6 | -0.17 | -1.74% | 4:00 PM EST | 841.35k | 906.65k | 1.32B |
| INO | Inovio Pharmaceuticals, Inc. | 5.54 | +0.02 | +0.36% | 4:00 PM EST | 207.75k | 291.05k | 143.84M |
BenzingaBioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical development across multiple solid tumors. Data from Summit Therapeutics Inc. (NASDAQ:SMMT) and their partner Akeso for ivonescimab (PD-1xVEGF bispecific) has shown the potential to challenge standard-of-care regimens across a range of solid tumors. The analyst notes that the data for ivonescimab have sparked interest in BioNTech’s bispecific drug, BNT327, and its potential to f
Motley Fool2 Magnificent S&P 500 Dividend Stocks Down Year to Date to Buy and Hold Forever
More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.
Insider MonkeyPfizer Inc. (PFE): Among the Best Low Volatility Stocks to Invest In Now
We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other low volatility stocks. We will also discuss the latest updates around the market and political situation of the US. Market Begins […]